<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Overview of the clinical manifestations of hyperthyroidism in adults</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Overview of the clinical manifestations of hyperthyroidism in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Overview of the clinical manifestations of hyperthyroidism in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 15, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The clinical manifestations of hyperthyroidism are largely independent of its cause. However, the disorder that causes hyperthyroidism may have other effects. In particular, Graves' disease, the most common cause of hyperthyroidism, causes unique problems that are not related to the high serum thyroid hormone concentrations. These include Graves' orbitopathy and infiltrative dermopathy (localized or pretibial myxedema). Most patients with Graves' hyperthyroidism have a diffuse goiter, but so do patients with other, less common causes of hyperthyroidism such as painless thyroiditis and thyroid-stimulating hormone (TSH)-secreting pituitary tumors.</p><p>The major clinical manifestations of hyperthyroidism (thyrotoxicosis) and its effects on specific organ systems will be reviewed here. More detailed discussions of its causes, as well as the diagnostic approach to patients with hyperthyroidism, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7871.html" rel="external">"Disorders that cause hyperthyroidism"</a> and  <a class="medical medical_review" href="/z/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H271901281"><span class="h1">CLASSIC SYMPTOMS</span><span class="headingEndMark"> — </span>Most patients with overt hyperthyroidism have a dramatic constellation of symptoms. The classic symptoms of hyperthyroidism include heat intolerance, tremor, palpitations, anxiety, weight loss despite a normal or increased appetite, increased frequency of bowel movements, and shortness of breath. Goiter is commonly found on physical examination. Patients with mild hyperthyroidism and older patients often have symptoms that are referable to one or only a few organ systems. (See  <a class="medical medical_review" href="/z/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism", section on 'Symptoms'</a>.)</p><p class="headingAnchor" id="H630607051"><span class="h1">SPECIFIC ORGAN SYSTEMS</span></p><p class="headingAnchor" id="H2"><span class="h2">Skin</span><span class="headingEndMark"> — </span>The skin is warm (and may rarely be erythematous) in hyperthyroidism due to increased blood flow; it is also smooth because of a decrease in the keratin layer [<a href="#rid1">1</a>]. Other changes include:</p><p class="bulletIndent1"><span class="glyph">●</span>Sweating, which increases due to increased calorigenesis; this is often associated with heat intolerance</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Onycholysis (loosening of the nails from the nail bed, Plummer's nails) and softening of the nails</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperpigmentation, which can occur in severe cases; it appears to be mediated by accelerated cortisol metabolism, leading to increased corticotropin (ACTH) secretion [<a href="#rid2">2</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pruritus and hives, which are occasional findings, primarily in patients with Graves' hyperthyroidism [<a href="#rid3">3</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vitiligo and alopecia areata, which can occur in association with autoimmune disorders</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thinning of the hair</p><p></p><p>Infiltrative dermopathy occurs only in patients with Graves' hyperthyroidism. The most common site is the skin overlying the shins, where it presents as raised, hyperpigmented, violaceous, orange-peel-textured papules. (See  <a class="medical medical_review" href="/z/d/html/7826.html" rel="external">"Pretibial myxedema (thyroid dermopathy) in autoimmune thyroid disease"</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Eyes</span><span class="headingEndMark"> — </span>Stare and lid lag occur in all patients with hyperthyroidism. They are due to sympathetic overactivity, possibly mediated by increased alpha-adrenergic receptors in some tissues [<a href="#rid4">4</a>]. Lid lag is evaluated by having the patient follow the examiner's finger as it is moved up and down. The patient has lid lag if sclera can be seen above the iris as the patient looks downward.</p><p>As noted above, only patients with Graves' disease have orbitopathy. It is characterized by inflammation of the extraocular muscles and orbital fat and connective tissue, which results in proptosis (exophthalmos), impairment of eye muscle function, and periorbital and conjunctival edema. Risk factors for developing Graves' orbitopathy include cigarette smoking, advancing age, and male sex [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/7825.html" rel="external">"Clinical features and diagnosis of thyroid eye disease"</a>.)</p><p>Patients with orbitopathy may have gritty feeling or pain in their eyes, and they may have diplopia due to extraocular muscle dysfunction. Corneal ulceration can occur as a result of proptosis and lid retraction, and severe proptosis can cause optic neuropathy and even blindness.</p><p class="headingAnchor" id="H4"><span class="h2">Cardiovascular</span><span class="headingEndMark"> — </span>Patients with hyperthyroidism have an increase in cardiac output, due both to increased peripheral oxygen needs and increased cardiac contractility. Heart rate is increased, pulse pressure is widened, and peripheral vascular resistance is decreased [<a href="#rid6">6</a>]. Systolic hypertension is common [<a href="#rid7">7</a>]. The left ventricular ejection fraction does not increase appropriately during exercise, suggesting the presence of a true cardiomyopathy [<a href="#rid8">8</a>]. High- or normal-output congestive heart failure can occur in patients with severe hyperthyroidism, and congestive heart failure worsens in patients who already have it. (See  <a class="medical medical_review" href="/z/d/html/7853.html" rel="external">"Cardiovascular effects of hyperthyroidism"</a>.)</p><p>Atrial fibrillation occurs in 10 to 20 percent of patients with hyperthyroidism, and it is more common in older patients. In one study, 8 percent of all patients and 15 percent of patients between ages 70 to 79 developed atrial fibrillation within 30 days of the diagnosis of hyperthyroidism [<a href="#rid9">9</a>]. Even subclinical hyperthyroidism is associated with an increased rate of atrial ectopy and a threefold increased risk of atrial fibrillation  (<a class="graphic graphic_figure graphicRef55024" href="/z/d/graphic/55024.html" rel="external">figure 1</a>) [<a href="#rid10">10</a>].</p><p>In 60 percent of hyperthyroid patients with atrial fibrillation, the rhythm converts spontaneously to sinus rhythm when the hyperthyroidism is treated; in one study, all who spontaneously converted did so within four months after becoming euthyroid [<a href="#rid11">11</a>]. Among those who do not convert spontaneously to sinus rhythm and who undergo successful electrical cardioversion, the two-year risk of recurrent atrial fibrillation was 59 percent compared with 83 percent of patients whose atrial fibrillation was not associated with hyperthyroidism [<a href="#rid12">12</a>].</p><p>Anticoagulation should be considered in hyperthyroid patients with atrial fibrillation. In several studies, 10 to 40 percent of patients with hyperthyroidism and atrial fibrillation had an arterial embolus [<a href="#rid13">13</a>]. Left atrial enlargement, which is a risk factor for thrombus formation, is present in approximately 90 percent of hyperthyroid patients with atrial fibrillation and 2 percent of hyperthyroid patients with sinus rhythm. Based on these results, we usually anticoagulate hyperthyroid patients with atrial fibrillation. The role of anticoagulant therapy in patients with hyperthyroidism and atrial fibrillation is reviewed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p><p>Other abnormalities, including mitral valve prolapse, mitral regurgitation, and an increase in left ventricular mass index have also been reported. (See  <a class="medical medical_review" href="/z/d/html/7853.html" rel="external">"Cardiovascular effects of hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H5"><span class="h2">Metabolic/Endocrine</span></p><p class="headingAnchor" id="H112337416"><span class="h3">Bone</span><span class="headingEndMark"> — </span>Thyroid hormone stimulates bone resorption, resulting in increased porosity of cortical bone and reduced volume of trabecular bone [<a href="#rid14">14</a>]. The loss in cortical bone density is greater than that of trabecular bone. Serum alkaline phosphatase and osteocalcin concentrations are high, indicative of increased bone turnover. The increase in bone resorption may lead to an increase in serum calcium concentrations, thereby inhibiting parathyroid hormone secretion and the conversion of calcidiol (25-hydroxyvitamin D) to calcitriol (1,25-dihydroxyvitamin D). In addition, the metabolic clearance rate of calcitriol is increased. These changes can result in impaired calcium absorption and an increase in urinary calcium excretion. The net effect is osteoporosis and an increased fracture risk in patients with chronic hyperthyroidism [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/z/d/html/7882.html" rel="external">"Bone disease with hyperthyroidism and thyroid hormone therapy"</a>.)</p><p>Graves' disease may also be associated with thyroid acropachy, with clubbing and periosteal new bone formation in the metacarpal bones or phalanges. Patients with thyroid acropachy commonly present with asymptomatic clubbing, severe ophthalmopathy, and dermopathy; a high percentage are cigarette smokers [<a href="#rid16">16</a>].</p><p class="headingAnchor" id="H6"><span class="h3">Serum lipids</span><span class="headingEndMark"> — </span>Patients with hyperthyroidism tend to have low serum total and high-density lipoprotein (HDL) cholesterol concentrations and a low total cholesterol/HDL cholesterol ratio. These values increase after treatment [<a href="#rid17">17</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Hyperglycemia</span><span class="headingEndMark"> — </span>Although thyroxine (T4) is not a counterregulatory hormone, hyperthyroidism can interfere with glucose metabolism. It is associated with both increased sensitivity of pancreatic beta cells to glucose, resulting in increased insulin secretion, and antagonism to the peripheral action of insulin [<a href="#rid18">18</a>]. The latter effect usually predominates, leading to impaired glucose tolerance in untreated patients [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H8"><span class="h3">Adrenal function</span><span class="headingEndMark"> — </span>Interpretation of the cortisol response to corticotropin (ACTH) stimulation testing may be misleading in patients with hyperthyroidism because corticosteroid-binding globulin (CBG) levels decrease, resulting in lower total serum cortisol concentrations. In one report of 49 hyperthyroid patients undergoing ACTH testing, 35 percent had subnormal total serum cortisol values (&lt;18 mcg/dL), while only 11 percent had a subnormal free cortisol index (ratio of serum total cortisol to CBG) [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Respiratory</span><span class="headingEndMark"> — </span>Dyspnea and dyspnea on exertion may occur for many reasons in hyperthyroidism (see  <a class="medical medical_review" href="/z/d/html/7865.html" rel="external">"Respiratory function in thyroid disease"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Oxygen consumption and carbon dioxide production increase. These changes result in hypoxemia and hypercapnia, respectively, both of which stimulate ventilation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory muscle weakness is an important cause of dyspnea [<a href="#rid21">21</a>], and reduced exercise capacity may be largely due to respiratory muscle weakness and decreased lung volume [<a href="#rid22">22</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There may be tracheal obstruction from a large goiter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hyperthyroidism may exacerbate underlying asthma.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary arterial systolic pressure is increased [<a href="#rid23">23</a>].</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Gastrointestinal</span><span class="headingEndMark"> — </span>Weight loss is due primarily to increased metabolic rate (hypermetabolism) and secondarily to increased gut motility and the associated hyperdefecation and malabsorption; rare patients have steatorrhea. Celiac disease is also more prevalent in patients with Graves' disease [<a href="#rid24">24</a>]. Most patients have hyperphagia, but an occasional patient with mild hyperthyroidism may have sufficient appetite stimulation that weight is gained (more commonly in younger patients) [<a href="#rid25">25</a>]. Anorexia may be prominent in older hyperthyroid patients [<a href="#rid26">26</a>].</p><p>Other changes that may occur include:</p><p class="bulletIndent1"><span class="glyph">●</span>Vomiting [<a href="#rid27">27</a>] and abdominal pain, rarely.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Dysphagia due to goiter.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Abnormalities in liver function tests, particularly high serum alkaline phosphatase concentrations and, rarely, cholestasis. In a meta-analysis, alanine transaminase (ALT) and aspartate transaminase (AST) were elevated in 33 and 23 percent of patients presenting with hyperthyroidism, respectively, while alkaline phosphatase was elevated in 44 percent of patients [<a href="#rid28">28</a>].</p><p></p><p class="headingAnchor" id="H2409653"><span class="h2">Thymic enlargement</span><span class="headingEndMark"> — </span>In patients with Graves' disease, thymic enlargement due to hyperplasia has been reported [<a href="#rid29">29-31</a>]. Thymic enlargement is usually discovered incidentally during the evaluation of other symptoms, such as dyspnea. The pathogenetic mechanism is unclear, but it is not a feature of hyperthyroidism due to causes other than Graves' disease. Potential mechanisms include autoimmune mediated (thyroid-stimulating immunoglobulins from patients with Graves' disease bind to the thyroid-stimulating hormone [TSH] receptor in the human thymus and cause thymocyte proliferation) and hyperthyroidism mediated (hyperthyroidism-induced angiogenesis) [<a href="#rid29">29,32</a>]. Causes of thymic enlargement other than Graves' disease should be considered. (See  <a class="medical medical_review" href="/z/d/html/6967.html" rel="external">"Approach to the adult patient with a mediastinal mass"</a>.)</p><p>In most patients, treatment of Graves' disease with antithyroid medications, radioiodine, or thyroidectomy results in involution of thymic hyperplasia over 4 to 25 months [<a href="#rid31">31</a>]. However, coexisting malignancies have been reported, and therefore, repeat imaging three to four months after initiation of therapy is warranted to ensure regression.</p><p class="headingAnchor" id="H11"><span class="h2">Hematologic</span><span class="headingEndMark"> — </span>The red blood cell mass is increased in hyperthyroidism, but the plasma volume is increased more, resulting in a normochromic, normocytic anemia [<a href="#rid33">33</a>]. Serum ferritin concentrations may be high.</p><p>Graves' hyperthyroidism may be associated with autoimmune hematologic disorders such as immune thrombocytopenia (ITP) and pernicious anemia, and some patients have antineutrophil antibodies. In a meta-analysis, 10 percent of patients presenting with Graves' hyperthyroidism had neutropenia [<a href="#rid34">34</a>].</p><p>Hyperthyroidism may also be prothrombotic [<a href="#rid35">35,36</a>]. As an example, in a meta-analysis of 51 studies evaluating the effect of thyroid hormone excess (exogenous or endogenous) on the coagulation system, excess thyroid hormone was associated with a rise in prothrombotic factors, including factors VIII, IX, fibrinogen, von Willebrand factor, and plasminogen activator inhibitor-1 [<a href="#rid36">36</a>]. Similar findings were noted in patients with either overt or subclinical hyperthyroidism.</p><p class="headingAnchor" id="H12"><span class="h2">Genitourinary</span><span class="headingEndMark"> — </span>Urinary frequency and nocturia are common in hyperthyroidism, although the mechanism is uncertain. Possible causes include primary polydipsia [<a href="#rid37">37</a>] and hypercalciuria. Enuresis is common in children.</p><p>In women, serum sex hormone-binding globulin (SHBG) concentrations are high, which results in high serum estradiol concentrations and low-normal serum free (unbound) estradiol concentrations, high serum luteinizing hormone (LH) concentrations, a reduced mid-cycle surge in LH secretion, oligomenorrhea, and anovulatory infertility [<a href="#rid38">38,39</a>]. Amenorrhea can occur in women with severe hyperthyroidism.</p><p>In men, the increase in serum SHBG concentrations results in high serum total testosterone concentrations, but serum free (unbound) testosterone concentrations are normal or low [<a href="#rid40">40,41</a>]. Serum LH concentrations may be slightly high. Extragonadal conversion of testosterone to estradiol is increased, so that serum estradiol concentrations are high. These changes can cause gynecomastia, reduced libido, and erectile dysfunction [<a href="#rid38">38,42</a>]. Spermatogenesis is often decreased or abnormal, eg, more spermatozoa are abnormal or nonmotile [<a href="#rid41">41</a>].</p><p class="headingAnchor" id="H14"><span class="h2">Neuropsychiatric</span><span class="headingEndMark"> — </span>Patients with thyrotoxicosis may experience behavioral and personality changes, such as psychosis, agitation, and depression. Less overt manifestations that are more common in less severe thyrotoxicosis include anxiety, restlessness, irritability, and emotional lability [<a href="#rid43">43</a>]. Insomnia is also common. Symptoms often worsen in patients with preexisting psychiatric disorders.</p><p>These behavioral manifestations are accompanied by cognitive impairments, particularly impaired concentration, confusion, poor orientation and immediate recall, amnesia, and constructional difficulties. Other neurologic manifestations are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4836.html" rel="external">"Neurologic manifestations of hyperthyroidism and Graves' disease"</a>.)</p><p class="headingAnchor" id="H3078698084"><span class="h1">THYROTOXIC PERIODIC PARALYSIS</span><span class="headingEndMark"> — </span>A rare presentation of thyrotoxicosis from any cause is periodic paralysis, marked muscle weakness associated with hypokalemia, frequently precipitated by exercise, fasting, or a high carbohydrate meal, and seen most frequently in East Asian males. (See  <a class="medical medical_review" href="/z/d/html/5154.html" rel="external">"Thyrotoxic periodic paralysis"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">GERIATRIC HYPERTHYROIDISM</span><span class="headingEndMark"> — </span>Hyperthyroidism in older patients may be apathetic, rather than having hyperactivity, tremor, and other symptoms of sympathetic overactivity [<a href="#rid44">44</a>]. However, two-thirds of such patients have symptoms similar to those in younger patients [<a href="#rid45">45</a>]. In cross-sectional studies of patients with hyperthyroidism, older patients had a reduced risk for the presence of several classical symptoms (ie, heat intolerance, tremor, nervousness) but a higher prevalence of weight loss and shortness of breath compared with younger patients [<a href="#rid45">45,46</a>]. Older patients also had a higher rate of atrial fibrillation and moderate to severe ophthalmopathy [<a href="#rid46">46</a>].</p><p>Older patients with Graves' hyperthyroidism are less likely to have a goiter. Toxic multinodular goiter is more common in older patients, although the majority of hyperthyroid patients at any age have Graves' hyperthyroidism. In addition, older patients often have persistent constipation. Tachycardia of 100 beats per minute is absent in 40 percent of older hyperthyroid patients, due primarily to coexistent conduction system disease.</p><p class="headingAnchor" id="H1180632645"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109107.html" rel="external">"Society guideline links: Hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H16"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15437.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/2178.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/2168.html" rel="external">"Patient education: Antithyroid drugs (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H17"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Classic symptoms</strong> – The classic symptoms of hyperthyroidism include weight loss, heat intolerance, tremor, palpitations, anxiety, increased frequency of bowel movements, and shortness of breath. Goiter is commonly found on physical examination. (See <a class="local">'Classic symptoms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mild hyperthyroidism</strong> – Patients with mild hyperthyroidism and older patients often have symptoms that are referable to one or only a few organ systems. (See <a class="local">'Specific organ systems'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms in older patients</strong> – Older patients may have fewer classical manifestations of hyperthyroidism. However, weight loss, shortness of breath, and atrial fibrillation occur more commonly in older than younger patients. (See <a class="local">'Geriatric hyperthyroidism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Findings unique to Graves' disease</strong> – Although the clinical manifestations of hyperthyroidism are largely independent of its cause, Graves' disease causes unique problems that are not related to the high serum thyroid hormone concentrations. These include Graves' orbitopathy and infiltrative dermopathy (localized or pretibial myxedema). (See  <a class="medical medical_review" href="/z/d/html/7825.html" rel="external">"Clinical features and diagnosis of thyroid eye disease"</a> and  <a class="medical medical_review" href="/z/d/html/7826.html" rel="external">"Pretibial myxedema (thyroid dermopathy) in autoimmune thyroid disease"</a>.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Heymann WR. Cutaneous manifestations of thyroid disease. J Am Acad Dermatol 1992; 26:885.</a></li><li><a class="nounderline abstract_t">KIRKEBY K, HANGAARD G, LINGJAERDE P. THE PIGMENTATION OF THYROTOXIC PATIENTS. Acta Med Scand 1963; 174:257.</a></li><li><a class="nounderline abstract_t">Collet E, Petit JM, Lacroix M, et al. [Chronic urticaria and autoimmune thyroid diseases]. Ann Dermatol Venereol 1995; 122:413.</a></li><li><a class="nounderline abstract_t">Bilezikian JP, Loeb JN. The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness. Endocr Rev 1983; 4:378.</a></li><li><a class="nounderline abstract_t">Lee MH, Chin YH, Ng CH, et al. Risk Factors of Thyroid Eye Disease. Endocr Pract 2021; 27:245.</a></li><li><a class="nounderline abstract_t">Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system: from theory to practice. J Clin Endocrinol Metab 1994; 78:1026.</a></li><li><a class="nounderline abstract_t">Iglesias P, Acosta M, Sánchez R, et al. Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 2005; 63:66.</a></li><li><a class="nounderline abstract_t">Forfar JC, Muir AL, Sawers SA, Toft AD. Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy. N Engl J Med 1982; 307:1165.</a></li><li><a class="nounderline abstract_t">Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004; 164:1675.</a></li><li><a class="nounderline abstract_t">Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249.</a></li><li><a class="nounderline abstract_t">Nakazawa HK, Sakurai K, Hamada N, et al. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 1982; 72:903.</a></li><li><a class="nounderline abstract_t">Siu CW, Jim MH, Zhang X, et al. Comparison of atrial fibrillation recurrence rates after successful electrical cardioversion in patients with hyperthyroidism-induced versus non-hyperthyroidism-induced persistent atrial fibrillation. Am J Cardiol 2009; 103:540.</a></li><li><a class="nounderline abstract_t">Bar-Sela S, Ehrenfeld M, Eliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med 1981; 141:1191.</a></li><li><a class="nounderline abstract_t">Ross DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994; 4:319.</a></li><li><a class="nounderline abstract_t">Williams GR, Bassett JHD. Thyroid diseases and bone health. J Endocrinol Invest 2018; 41:99.</a></li><li><a class="nounderline abstract_t">Fatourechi V, Ahmed DD, Schwartz KM. Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period. J Clin Endocrinol Metab 2002; 87:5435.</a></li><li><a class="nounderline abstract_t">O'Brien T, Katz K, Hodge D, et al. The effect of the treatment of hypothyroidism and hyperthyroidism on plasma lipids and apolipoproteins AI, AII and E. Clin Endocrinol (Oxf) 1997; 46:17.</a></li><li><a class="nounderline abstract_t">Reasner CA. Autoimmune thyroid disease and type 1 diabetes. Diabetes Reviews 1993; 1:343.</a></li><li><a class="nounderline abstract_t">Andersen OO, Friis T, Ottesen B. Glucose tolerance and insulin secretion in hyperthyroidism. Acta Endocrinol (Copenh) 1977; 84:576.</a></li><li><a class="nounderline abstract_t">Mishra SK, Gupta N, Goswami R. Plasma adrenocorticotropin (ACTH) values and cortisol response to 250 and 1 microg ACTH stimulation in patients with hyperthyroidism before and after carbimazole therapy: case-control comparative study. J Clin Endocrinol Metab 2007; 92:1693.</a></li><li><a class="nounderline abstract_t">Ayres J, Rees J, Clark TJ, Maisey MN. Thyrotoxicosis and dyspnoea. Clin Endocrinol (Oxf) 1982; 16:65.</a></li><li><a class="nounderline abstract_t">Kahaly G, Hellermann J, Mohr-Kahaly S, Treese N. Impaired cardiopulmonary exercise capacity in patients with hyperthyroidism. Chest 1996; 109:57.</a></li><li><a class="nounderline abstract_t">Mercé J, Ferrás S, Oltra C, et al. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. Am J Med 2005; 118:126.</a></li><li><a class="nounderline abstract_t">Ch'ng CL, Biswas M, Benton A, et al. Prospective screening for coeliac disease in patients with Graves' hyperthyroidism using anti-gliadin and tissue transglutaminase antibodies. Clin Endocrinol (Oxf) 2005; 62:303.</a></li><li><a class="nounderline abstract_t">Nordyke RA, Gilbert FI Jr, Harada AS. Graves' disease. Influence of age on clinical findings. Arch Intern Med 1988; 148:626.</a></li><li><a class="nounderline abstract_t">Davis PJ, Davis FB. Hyperthyroidism in patients over the age of 60 years. Clinical features in 85 patients. Medicine (Baltimore) 1974; 53:161.</a></li><li><a class="nounderline abstract_t">Rosenthal FD, Jones C, Lewis SI. Thyrotoxic vomiting. Br Med J 1976; 2:209.</a></li><li><a class="nounderline abstract_t">Scappaticcio L, Longo M, Maiorino MI, et al. Abnormal Liver Blood Tests in Patients with Hyperthyroidism: Systematic Review and Meta-Analysis. Thyroid 2021; 31:884.</a></li><li><a class="nounderline abstract_t">Dalla Costa M, Mangano FA, Betterle C. Thymic hyperplasia in patients with Graves' disease. J Endocrinol Invest 2014; 37:1175.</a></li><li><a class="nounderline abstract_t">Yacoub A, Gaitonde DY, Wood JC. Thymic hyperplasia and Graves disease: management of anterior mediastinal masses in patients with Graves disease. Endocr Pract 2009; 15:534.</a></li><li><a class="nounderline abstract_t">Huang W, Molitch ME. Enlarged thymus in a patient with dyspnea and weight loss. JAMA 2015; 313:2174.</a></li><li><a class="nounderline abstract_t">Wortsman J, McConnachie P, Baker JR Jr, Burman KD. Immunoglobulins that cause thymocyte proliferation from a patient with Graves' disease and an enlarged thymus. Am J Med 1988; 85:117.</a></li><li><a class="nounderline abstract_t">Nightingale S, Vitek PJ, Himsworth RL. The haematology of hyperthyroidism. Q J Med 1978; 47:35.</a></li><li><a class="nounderline abstract_t">Scappaticcio L, Maiorino MI, Maio A, et al. Neutropenia in patients with hyperthyroidism: Systematic review and meta-analysis. Clin Endocrinol (Oxf) 2021; 94:473.</a></li><li><a class="nounderline abstract_t">Franchini M, Lippi G, Targher G. Hyperthyroidism and venous thrombosis: a casual or causal association? A systematic literature review. Clin Appl Thromb Hemost 2011; 17:387.</a></li><li><a class="nounderline abstract_t">Stuijver DJ, van Zaane B, Romualdi E, et al. The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis. Thromb Haemost 2012; 108:1077.</a></li><li><a class="nounderline abstract_t">Evered DC, Hayter CJ, Surveyor I. Primary polydipsia in thyrotoxicosis. Metabolism 1972; 21:393.</a></li><li><a class="nounderline abstract_t">Ridgway EC, Maloof F, Longcope C. Androgen and oestrogen dynamics in hyperthyroidism. J Endocrinol 1982; 95:105.</a></li><li><a class="nounderline abstract_t">Koutras DA. Disturbances of menstruation in thyroid disease. Ann N Y Acad Sci 1997; 816:280.</a></li><li><a class="nounderline abstract_t">Hudson RW, Edwards AL. Testicular function in hyperthyroidism. J Androl 1992; 13:117.</a></li><li><a class="nounderline abstract_t">Abalovich M, Levalle O, Hermes R, et al. Hypothalamic-pituitary-testicular axis and seminal parameters in hyperthyroid males. Thyroid 1999; 9:857.</a></li><li><a class="nounderline abstract_t">Carani C, Isidori AM, Granata A, et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 2005; 90:6472.</a></li><li><a class="nounderline abstract_t">Stern RA, Robinson B, Thorner AR, et al. A survey study of neuropsychiatric complaints in patients with Graves' disease. J Neuropsychiatry Clin Neurosci 1996; 8:181.</a></li><li><a class="nounderline abstract_t">Thomas FB, Mazzaferri EL, Skillman TG. Apathetic thyrotoxicosis: A distinctive clinical and laboratory entity. Ann Intern Med 1970; 72:679.</a></li><li><a class="nounderline abstract_t">Trivalle C, Doucet J, Chassagne P, et al. Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 1996; 44:50.</a></li><li><a class="nounderline abstract_t">Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 2010; 95:2715.</a></li></ol></div><div id="topicVersionRevision">Topic 7833 Version 20.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1607406" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cutaneous manifestations of thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14058749" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : THE PIGMENTATION OF THYROTOXIC PATIENTS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8526423" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : [Chronic urticaria and autoimmune thyroid diseases].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6317368" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33655885" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Risk Factors of Thyroid Eye Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8175954" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Thyroid hormone and the cardiovascular system: from theory to practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15963064" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7121544" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15302638" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7935681" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7091161" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Management of atrial fibrillation in the post-thyrotoxic state.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19195517" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparison of atrial fibrillation recurrence rates after successful electrical cardioversion in patients with hyperthyroidism-induced versus non-hyperthyroidism-induced persistent atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7259379" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Arterial embolism in thyrotoxicosis with atrial fibrillation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7833670" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Hyperthyroidism, thyroid hormone therapy, and bone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28853052" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Thyroid diseases and bone health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12466333" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9059553" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The effect of the treatment of hypothyroidism and hyperthyroidism on plasma lipids and apolipoproteins AI, AII and E.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Autoimmune thyroid disease and type 1 diabetes</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/320805" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Glucose tolerance and insulin secretion in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17327382" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Plasma adrenocorticotropin (ACTH) values and cortisol response to 250 and 1 microg ACTH stimulation in patients with hyperthyroidism before and after carbimazole therapy: case-control comparative study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7074972" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Thyrotoxicosis and dyspnoea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8549218" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Impaired cardiopulmonary exercise capacity in patients with hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15694895" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15730411" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Prospective screening for coeliac disease in patients with Graves' hyperthyroidism using anti-gliadin and tissue transglutaminase antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3341864" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Graves' disease. Influence of age on clinical findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4133091" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Hyperthyroidism in patients over the age of 60 years. Clinical features in 85 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/974494" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Thyrotoxic vomiting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33327837" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Abnormal Liver Blood Tests in Patients with Hyperthyroidism: Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25149085" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Thymic hyperplasia in patients with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19491074" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Thymic hyperplasia and Graves disease: management of anterior mediastinal masses in patients with Graves disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26034958" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Enlarged thymus in a patient with dyspnea and weight loss.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3260449" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Immunoglobulins that cause thymocyte proliferation from a patient with Graves' disease and an enlarged thymus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/674549" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The haematology of hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32799342" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Neutropenia in patients with hyperthyroidism: Systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20308227" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Hyperthyroidism and venous thrombosis: a casual or causal association? A systematic literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23014708" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4111512" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Primary polydipsia in thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7130886" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Androgen and oestrogen dynamics in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9238278" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Disturbances of menstruation in thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1597395" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Testicular function in hyperthyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10524563" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Hypothalamic-pituitary-testicular axis and seminal parameters in hyperthyroid males.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16204360" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9081554" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : A survey study of neuropsychiatric complaints in patients with Graves' disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4194420" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Apathetic thyrotoxicosis: A distinctive clinical and laboratory entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8537590" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Differences in the signs and symptoms of hyperthyroidism in older and younger patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20392869" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
